Literature DB >> 24702172

Reductions in resistance exercise-induced hyperglycaemic episodes are associated with circulating interleukin-6 in type 1 diabetes.

D Turner1, S Luzio, L P Kilduff, B J Gray, G Dunseath, S C Bain, M D Campbell, D J West, R M Bracken.   

Abstract

AIMS: To determine the influence of different volumes of resistance exercise on circulating interleukin-6 (IL-6) and to explore the relationships between IL-6 and glycaemia.
METHODS: Eight participants with complication-free type 1 diabetes, whose mean ± SEM age was 38 (6) years, mean ± SEM HbA(1c) concentration was 71 ±11 mmol/mol (8.7 ±1.0%) and mean ± SEM type 1 diabetes duration was 15 ±13 years, attended the research facility after an overnight fast on four separate occasions, having administered their basal insulin the night before (glargine 27.5±3.1U, n=8), but omitted morning rapid-acting insulin. Participants completed either a one-set (14-min), two-set (28-min), or three-set (42-min) resistance exercise trial (eight exercises × 10 repetitions) at 67±3% one-repetition maximum followed by a 60-min recovery, or a resting control trial. Venous blood samples were taken before and after exercise. Data were analysed using repeated-measures ANOVA (P≤0.05).
RESULTS: Whereas IL-6 levels remained similar to baseline levels after one set of resistance exercises (30 min, P=0.287; 60 min, P=0.318), IL-6 levels were > baseline levels at 60 min post-exercise after a two-set exercise trial (2.94 ± 0.94 pg/ml, P=0.002) and doubled at both 30 min (4.01 ± 1.00 pg/ml, P=0.048) and 60 min (4.28 ± 1.25 pg/ml, P=0.084) post-exercise after the three-set resistance exercise trial. Post-exercise blood glucose area under the curve (mmol/l/60 min) was greater after both the one-set (P=0.025) and two-set trials (P=0.008), than after the control trial, but similar between the three-set trial and the control trial (P=0.240). The rise in IL-6 from baseline to peak concentration significantly correlated inversely with blood glucose area under the curve (r=-0.65, P=0.041).
CONCLUSIONS: Circulating IL-6 is increased by resistance exercise in a volume-dependent manner, and resistance exercise-induced increases in IL-6 correlated with reductions in post-exercise hyperglycaemia in type 1 diabetes, suggesting a role for IL-6 in improving post-resistance exercise glycaemic disturbances in type 1 diabetes.
© 2014 The Authors. Diabetic Medicine © 2014 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24702172     DOI: 10.1111/dme.12462

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

1.  Reassessing the evidence: prandial state dictates glycaemic responses to exercise in individuals with type 1 diabetes to a greater extent than intensity.

Authors:  Jane E Yardley
Journal:  Diabetologia       Date:  2022-08-18       Impact factor: 10.460

Review 2.  Continuous Glucose Monitoring and Exercise in Type 1 Diabetes: Past, Present and Future.

Authors:  Shaelyn K Houlder; Jane E Yardley
Journal:  Biosensors (Basel)       Date:  2018-08-03

Review 3.  Resistance Isn't Futile: The Physiological Basis of the Health Effects of Resistance Exercise in Individuals With Type 1 Diabetes.

Authors:  Olivia McCarthy; Othmar Moser; Max L Eckstein; Rachel Deere; Steve C Bain; Jason Pitt; Richard M Bracken
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

Review 4.  Factors Influencing Insulin Absorption Around Exercise in Type 1 Diabetes.

Authors:  Jason P Pitt; Olivia M McCarthy; Thomas Hoeg-Jensen; Benjamin M Wellman; Richard M Bracken
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

5.  Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial.

Authors:  Lauren L O'Mahoney; Gareth Dunseath; Rachel Churm; Mel Holmes; Christine Boesch; Antonios Stavropoulos-Kalinoglou; Ramzi A Ajjan; Karen M Birch; Nicolas M Orsi; Georgia Mappa; Oliver J Price; Matthew D Campbell
Journal:  Cardiovasc Diabetol       Date:  2020-08-12       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.